Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program?
Cancer J
.
2014 Jan-Feb;20(1):25-6.
doi: 10.1097/PPO.0000000000000022.
Author
Mario Sznol
1
Affiliation
1
Yale Cancer Center, New Haven, CT.
PMID:
24445760
DOI:
10.1097/PPO.0000000000000022
No abstract available
Publication types
Comment
MeSH terms
Female
Humans
Indoles / therapeutic use*
Male
Melanoma / drug therapy*
Skin Neoplasms / drug therapy*
Sulfonamides / therapeutic use*
Vemurafenib
Substances
Indoles
Sulfonamides
Vemurafenib